Publisert 21.12.2020

EGM January 4th 2021

January 4th 2021

Extraordinary Annual Meeting January 4th 2021. (Video/phone)

(only one agenda point: VPS registration of shares)


 Notice EGM January 4th 2021 

Protocol EGF January 4th 2021  

For questions, please notify CEO Henrik Lund, +47 90971219

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.